Literature DB >> 25344580

Tumor-associated macrophages in SHH subgroup of medulloblastomas.

Ashley S Margol1, Nathan J Robison1, Janahan Gnanachandran2, Long T Hung2, Rebekah J Kennedy2, Marzieh Vali2, Girish Dhall1, Jonathan L Finlay1, Anat Erdreich-Epstein3, Mark D Krieger1, Rachid Drissi4, Maryam Fouladi4, Floyd H Gilles1, Alexander R Judkins5, Richard Sposto1, Shahab Asgharzadeh6.   

Abstract

PURPOSE: Medulloblastoma in children can be categorized into at least four molecular subgroups, offering the potential for targeted therapeutic approaches to reduce treatment-related morbidities. Little is known about the role of tumor microenvironment in medulloblastoma or its contribution to these molecular subgroups. Tumor microenvironment has been shown to be an important source for therapeutic targets in both adult and pediatric neoplasms. In this study, we investigated the hypothesis that expression of genes related to tumor-associated macrophages (TAM) correlates with the medulloblastoma molecular subgroups and contributes to a diagnostic signature.
METHODS: Gene-expression profiling using human exon array (n = 168) was analyzed to identify medulloblastoma molecular subgroups and expression of inflammation-related genes. Expression of 45 tumor-related and inflammation-related genes was analyzed in 83 medulloblastoma samples to build a gene signature predictive of molecular subgroups. TAMs in medulloblastomas (n = 54) comprising the four molecular subgroups were assessed by immunohistochemistry (IHC).
RESULTS: A 31-gene medulloblastoma subgroup classification score inclusive of TAM-related genes (CD163 and CSF1R) was developed with a misclassification rate of 2%. Tumors in the Sonic Hedgehog (SHH) subgroup had increased expression of inflammation-related genes and significantly higher infiltration of TAMs than tumors in the Group 3 or Group 4 subgroups (P < 0.0001 and P < 0.0001, respectively). IHC data revealed a strong association between location of TAMs and proliferating tumor cells.
CONCLUSIONS: These data show that SHH tumors have a unique tumor microenvironment among medulloblastoma subgroups. The interactions of TAMs and SHH medulloblastoma cells may contribute to tumor growth revealing TAMs as a potential therapeutic target. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25344580     DOI: 10.1158/1078-0432.CCR-14-1144

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  44 in total

1.  Know your neighbors: Different tumor microenvironments have implications in immunotherapeutic targeting strategies across MB subgroups.

Authors:  Christina D Pham; Duane A Mitchell
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

2.  Chemoradiation impairs normal developmental cortical thinning in medulloblastoma.

Authors:  Palak Kundu; Matthew D Li; Ben Y Durkee; Susan M Hiniker; Karl Bush; Rie von Eyben; Michelle L Monje; Kristen W Yeom; Sarah S Donaldson; Iris C Gibbs
Journal:  J Neurooncol       Date:  2017-05-22       Impact factor: 4.130

3.  Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.

Authors:  Christina D Pham; Catherine Flores; Changlin Yang; Elaine M Pinheiro; Jennifer H Yearley; Elias J Sayour; Yanxin Pei; Colin Moore; Roger E McLendon; Jianping Huang; John H Sampson; Robert Wechsler-Reya; Duane A Mitchell
Journal:  Clin Cancer Res       Date:  2015-09-24       Impact factor: 12.531

Review 4.  Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies.

Authors:  C Raggi; H S Mousa; M Correnti; A Sica; P Invernizzi
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

5.  Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.

Authors:  Stefan Blüml; Ashley S Margol; Richard Sposto; Rebekah J Kennedy; Nathan J Robison; Marzieh Vali; Long T Hung; Sakunthala Muthugounder; Jonathan L Finlay; Anat Erdreich-Epstein; Floyd H Gilles; Alexander R Judkins; Mark D Krieger; Girish Dhall; Marvin D Nelson; Shahab Asgharzadeh
Journal:  Neuro Oncol       Date:  2015-08-08       Impact factor: 12.300

6.  Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy.

Authors:  Lucie Lafay-Cousin; Amy Smith; Susan N Chi; Elizabeth Wells; Jennifer Madden; Ashley Margol; Vijay Ramaswamy; Jonathan Finlay; Michael D Taylor; Girish Dhall; Douglas Strother; Mark W Kieran; Nicholas K Foreman; Roger J Packer; Eric Bouffet
Journal:  Pediatr Blood Cancer       Date:  2016-05-04       Impact factor: 3.167

7.  An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.

Authors:  Thomas K Albert; Marta Interlandi; Martin Sill; Monika Graf; Natalia Moreno; Kerstin Menck; Astrid Rohlmann; Viktoria Melcher; Sonja Korbanka; Gerd Meyer Zu Hörste; Tobias Lautwein; Michael C Frühwald; Christian F Krebs; Dörthe Holdhof; Melanie Schoof; Annalen Bleckmann; Markus Missler; Martin Dugas; Ulrich Schüller; Natalie Jäger; Stefan M Pfister; Kornelius Kerl
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

Review 8.  Immune profiling of pediatric solid tumors.

Authors:  Rachael L Terry; Deborah Meyran; David S Ziegler; Michelle Haber; Paul G Ekert; Joseph A Trapani; Paul J Neeson
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

9.  Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens.

Authors:  Kee Kiat Yeo; Ashley S Margol; Rebekah J Kennedy; Long Hung; Nathan J Robison; Girish Dhall; Shahab Asgharzadeh
Journal:  J Neurooncol       Date:  2019-10-16       Impact factor: 4.130

10.  Subgroup-specific immune and stromal microenvironment in medulloblastoma.

Authors:  Michael Bockmayr; Malte Mohme; Frederick Klauschen; Beate Winkler; Jan Budczies; Stefan Rutkowski; Ulrich Schüller
Journal:  Oncoimmunology       Date:  2018-05-24       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.